BioCentury | Sep 19, 2020
Translation in Brief

Gene therapies from Passage Bio, Locanabio; Lava’s antitumor bispecific, health disparities in Alzheimer’s and more

...activity and corrected microgliosis in mouse models of frontotemporal dementia caused by GRN mutations. Intra-cisterna magna...
BioCentury | Aug 14, 2019
Financial News

D&D raises $137M to fund inflammation tech out of JHU

...is inflammation. Octave Life Sciences and Smilegate Investments co-led the round, with participation from InterVest, Magna...
BioCentury | Mar 21, 2019
Emerging Company Profile

A Passage to optimal CNS vectors

...primate data, Passage will probably inject its GM1 and FTD gene therapies into the cisterna magna...
BioCentury | Jan 10, 2019
Emerging Company Profile

Kleo: small molecule immuno-oncology

...status: Preclinical Founded: 2015 by David Spiegel and Roy Prieb University collaborators: Yale University and Magna...
BioCentury | Sep 20, 2018
Distillery Therapeutics

Autoimmune disease

...MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, injection into the cisterna magna...
...followed by laser light targeted to five locations on the intact skull -- the cisterna magna...
BioCentury | Jul 20, 2018
Financial News

Neuraly raises $36M series A to develop microglia-targeted PD candidate

...led by new investor D&D Pharmatech (Gyeonggi-do, Korea). Korean venture funds Smilegate, InterVest, LB Investment, Magna...
...and undisclosed private investors. Smilegate's John Ku, Maryland Venture's Phillip Jung, InterVest's Junghee Lim and Magna's...
BioCentury | Jul 18, 2018
Financial News

Neuraly debuts with $36M to target neurodegenerative diseases

...led by new investor D&D Pharmatech (Gyeonggi-do, Korea). Korean venture funds Smilegate, InterVest, LB Investment, Magna...
...and undisclosed private investors. Smilegate's John Ku, Maryland Venture's Phillip Jung, InterVest's Junghee Lim and Magna's...
BioCentury | Oct 3, 2017
Distillery Therapeutics

Autoimmune disease

...In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, intrathecal transplant into the cisterna magna...
...of TGFB2-knockout NSCs had no effect. Also in the model, intrathecal injection into the cisterna magna...
BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...Active Motif Inc. Lysine-specific demethylases Cancer Preclinical $15.0 Alexandria Venture Investments; Evotec AG (Xetra:EVT) ; Magna...
BioCentury | Jun 27, 2016
Company News

Roche, Tib Molbiol sales and marketing update

...The test is able to process 96 plasma samples in two hours utilizing the Roche MagNA...
Items per page:
1 - 10 of 16
BioCentury | Sep 19, 2020
Translation in Brief

Gene therapies from Passage Bio, Locanabio; Lava’s antitumor bispecific, health disparities in Alzheimer’s and more

...activity and corrected microgliosis in mouse models of frontotemporal dementia caused by GRN mutations. Intra-cisterna magna...
BioCentury | Aug 14, 2019
Financial News

D&D raises $137M to fund inflammation tech out of JHU

...is inflammation. Octave Life Sciences and Smilegate Investments co-led the round, with participation from InterVest, Magna...
BioCentury | Mar 21, 2019
Emerging Company Profile

A Passage to optimal CNS vectors

...primate data, Passage will probably inject its GM1 and FTD gene therapies into the cisterna magna...
BioCentury | Jan 10, 2019
Emerging Company Profile

Kleo: small molecule immuno-oncology

...status: Preclinical Founded: 2015 by David Spiegel and Roy Prieb University collaborators: Yale University and Magna...
BioCentury | Sep 20, 2018
Distillery Therapeutics

Autoimmune disease

...MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, injection into the cisterna magna...
...followed by laser light targeted to five locations on the intact skull -- the cisterna magna...
BioCentury | Jul 20, 2018
Financial News

Neuraly raises $36M series A to develop microglia-targeted PD candidate

...led by new investor D&D Pharmatech (Gyeonggi-do, Korea). Korean venture funds Smilegate, InterVest, LB Investment, Magna...
...and undisclosed private investors. Smilegate's John Ku, Maryland Venture's Phillip Jung, InterVest's Junghee Lim and Magna's...
BioCentury | Jul 18, 2018
Financial News

Neuraly debuts with $36M to target neurodegenerative diseases

...led by new investor D&D Pharmatech (Gyeonggi-do, Korea). Korean venture funds Smilegate, InterVest, LB Investment, Magna...
...and undisclosed private investors. Smilegate's John Ku, Maryland Venture's Phillip Jung, InterVest's Junghee Lim and Magna's...
BioCentury | Oct 3, 2017
Distillery Therapeutics

Autoimmune disease

...In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, intrathecal transplant into the cisterna magna...
...of TGFB2-knockout NSCs had no effect. Also in the model, intrathecal injection into the cisterna magna...
BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...Active Motif Inc. Lysine-specific demethylases Cancer Preclinical $15.0 Alexandria Venture Investments; Evotec AG (Xetra:EVT) ; Magna...
BioCentury | Jun 27, 2016
Company News

Roche, Tib Molbiol sales and marketing update

...The test is able to process 96 plasma samples in two hours utilizing the Roche MagNA...
Items per page:
1 - 10 of 16